<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="45783">Imatinib</z:chebi> (STI571, <z:chebi fb="0" ids="31690">Gleevec</z:chebi>/<z:chebi fb="0" ids="31690">Glivec</z:chebi>) and other small-molecule <z:chebi fb="0" ids="38637">tyrosine kinase inhibitors</z:chebi> are highly effective in the treatment of <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>), <z:hpo ids='HP_0100723'>gastrointestinal stromal tumors</z:hpo> and, for example, <z:hpo ids='HP_0001880'>eosinophilia</z:hpo>-associated <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>This molecularly targeted approach disrupts abnormal tyrosine kinase dependent signalling pathways, thus providing a preferred treatment option for selected neoplastic disorders with activating mutations of Abelson-, Abl-related-, Kit-, and platelet-derived growth factor receptor A and B genes </plain></SENT>
<SENT sid="2" pm="."><plain>Loss of response to <z:chebi fb="0" ids="45783">imatinib</z:chebi> may be due to an acquired resistance of emerging mutant <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell clones </plain></SENT>
<SENT sid="3" pm="."><plain>Therapy is generally well tolerated </plain></SENT>
<SENT sid="4" pm="."><plain>However, toxicities including <z:hpo ids='HP_0000969'>edema</z:hpo>, skin <z:e sem="disease" ids="C0015230" disease_type="Disease or Syndrome" abbrv="">rashes</z:e>, <z:mp ids='MP_0002899'>fatigue</z:mp>, <z:hpo ids='HP_0002018'>nausea</z:hpo> and <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e> have been reported </plain></SENT>
<SENT sid="5" pm="."><plain>Philadelphia/Bcr-Abl-negative clonal chromosomal abnormalities may develop </plain></SENT>
<SENT sid="6" pm="."><plain>Bone marrow trephines obtained from <z:mp ids='MP_0005481'>CML</z:mp> patients in complete remission with prolonged <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> secondary to <z:chebi fb="0" ids="45783">imatinib</z:chebi> generally show marrow <z:mpath ids='MPATH_133'>hypoplasia</z:mpath> </plain></SENT>
<SENT sid="7" pm="."><plain>Morphological features may be in keeping with either <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> or <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> developing in Philadelphia-negative hematopoiesis </plain></SENT>
<SENT sid="8" pm="."><plain>Single or multilineage <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> may be accompanied by an excess of blasts and rarely evolves into <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> in <z:mp ids='MP_0005481'>CML</z:mp> patients </plain></SENT>
<SENT sid="9" pm="."><plain>Severe adverse hematological effects of <z:chebi fb="0" ids="45783">imatinib</z:chebi> are extremely rare </plain></SENT>
<SENT sid="10" pm="."><plain>Current questions involve the molecular mechanisms of hematological side effects of <z:chebi fb="0" ids="38637">tyrosine kinase inhibitors</z:chebi> with special regard to the emergence of distinct aberrant clones </plain></SENT>
</text></document>